Genotypic characterisation of vancomycin-resistant Enterococcus faecium isolates from haemato-oncological patients at Olomouc University Hospital, Czech Republic  by Kolar, M. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01365.x
Genotypic characterisation of vancomycin-resistant Enterococcus faecium
isolates from haemato-oncological patients at Olomouc University
Hospital, Czech Republic
M. Kolar1, R. Pantucek2, I. Vagnerova1, M. Kesselova1, P. Sauer1, I. Matouskova3, J. Doskar2,
D. Koukalova1 and P. Hejnar1
1Department of Microbiology, Faculty of Medicine, Palacky University, Olomouc, 2Department of
Genetics and Molecular Biology, Faculty of Sciences, Masaryk University, Brno and 3Department of
Preventive Medicine, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
ABSTRACT
This study describes the ﬁrst molecular characterisation of clinical isolates of vancomycin-resistant
enterococci (VRE) in the Czech Republic. Of 2647 patient isolates of Enterococcus spp. from 1997–2002,
121 (4.6%) were identiﬁed as VRE. The most common isolates were VanA+ Enterococcus faecium (78%)
and VanB+ Enterococcus faecalis (10%). In addition, ﬁve VanA+ E. faecium isolates were obtained from
environmental and staff sampling. Macrorestriction analysis of SmaI restriction fragment length
polymorphism was performed for 54 VanA+ E. faecium clinical isolates and the ﬁve VanA+ E. faecium
environmental isolates. Thirty-two unique restriction endonuclease patterns were identiﬁed, including
two predominant clonal types represented by ﬁve or more isolates. Two environmental VanA+
E. faecium isolates were closely related to two patient isolates, which had an identical SmaI
macrorestriction pattern. The results indicated potential survival of strains in the hospital environment
and possible subsequent transmission to hospitalised patients.
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INTRODUCTION
The myelosuppressive and immunosuppressive
effects of cytostatic agents result in the defensive
capacities of haemato-oncological patients against
infection being decreased markedly, such that
bacterial infections have a signiﬁcant inﬂuence on
a patient’s prognosis [1]. The microorganisms
responsible for infectionmaybepart of theprimary
bacterial microﬂora present at the time of hospi-
talisation; however, more frequently, these organ-
isms are secondary colonisers of patients’ mucosae
as a consequence of various factors related to
hospitalisation (e.g., length of stay, chemotherapy
or administration of antibiotics).
During the past two decades, there has been a
signiﬁcant increase in Gram-positive bacteria (i.e.,
staphylococci and enterococci) associated with the
occurrence of febrile attacks in haemato-oncolog-
ical patients with neutropenia [2,3]. These bacter-
ial strains are often multiresistant to antibiotics,
and methicillin-resistant staphylococci and vanco-
mycin-resistant enterococci (VRE) pose a serious
therapeutic problem. VRE were ﬁrst described in
Europe in 1987, and were ﬁrst isolated in haem-
atological departments and transplant units. Since
1988, their incidence has increased worldwide [4–
7]. The main risk-factor for their occurrence is
excessive use of glycopeptides, but use of third-
generation cephalosporins and ﬂuoroquinolones
is also involved in the selection of VRE [8,9].
The aim of the present study was to investigate
the genetic relationships among VanA+ Enterococ-
cus faecium isolates from clinical specimens
obtained from patients at the Department of
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Haemato-Oncology (DHO), Olomouc University
Hospital, Czech Republic, and also among iso-
lates obtained from the DHO environment, inclu-
ding staff members, during 1997–2002. The results
obtained were used to formulate a hypothesis
concerning the sources and spread of VRE.
MATERIALS AND METHODS
Isolation of bacterial strains
Enterococci were isolated during the period 1997–2002 by
standard cultivation methods from clinical specimens (upper
respiratory tract, rectal and vaginal swabs, sputum, blood,
urine, pus, exudates) obtained from all hospitalised patients in
the DHO, as well as from specimens (rectal, nasal, hand and
hair surface swabs) obtained from DHO staff members.
In addition, samples were taken from the DHO environ-
ment. Sterile cotton swabs were immersed in sterile water and
applied to an area of 100 mm2 or an entire small object. Each
swab was immediately immersed in 5 mL of Brewer thiogly-
collate medium (Becton Dickinson, Heidelberg, Germany) and
incubated for 48 h at 37C. A calibrated loop was then used to
inoculate plates of Columbia blood agar containing sheep
blood 7% v ⁄v, which were then incubated aerobically at 37C
for 48 h. Enterococci were identiﬁed according to the
criteria established by Facklam and Collins [10] and with the
En-coccus test (Pliva Lachema, Brno, Czech Republic).
Identiﬁcation of VRE and glycopeptide resistance
determinants
Resistance to vancomycin and teicoplanin, as well as to
ampicillin, chloramphenicol, tetracycline, erythromycin,
nitrofurantoin, quinupristin–dalfopristin and linezolid, and
high-level resistance to gentamicin and streptomycin, were
determined by a standardised dilution micromethod [11].
The breakpoints for susceptibility were set at vancomycin
4 mg ⁄L and teicoplanin 8 mg ⁄L. Glycopeptide resistance
phenotypes were determined by preparing vancomycin and
teicoplanin at concentrations of 2–1024 mg ⁄L. Standard
reference strains used were Staphylococcus aureus
ATCC 29213 and Enterococcus faecalis ATCC 29212. Species
identiﬁcation and glycopeptide resistance genotypes of
vancomycin-resistant isolates were determined by multiplex
PCR as described previously [12].
Surveillance methods
The frequency of isolation of all enterococci, including VRE,
was determined at yearly intervals. Occurrence of VRE was
also expressed in terms of the number of VRE ⁄number of
DHO bed-days at yearly intervals. Duplicate isolates from the
same patient and clinical material were counted once during a
calendar year.
Genotyping by pulsed-ﬁeld gel electrophoresis
Macrorestriction analysis by pulsed-ﬁeld gel electrophoresis
(PFGE) was performed for 59 non-duplicate VanA+ E. faecium
isolates. Preparation of chromosomal DNA and digestion
with SmaI were performed according to Kolar et al. [13] with
the following modiﬁcations. SmaI restriction fragments were
separated in agarose 1.2% w ⁄v gels (Serva Electrophoresis,
Heidelberg, Germany), 21 cm in length, in 1 · TAE (0.04 M
Tris-acetate, 0.001 M EDTA, pH 8.2) electrophoresis buffer at
14C in a CHEF-Mapper apparatus (Bio-Rad, Hercules, CA,
USA) under multistate program conditions: ﬁrst, run time
22 h, initial switch time 0.1 s, ﬁnal switch time 6.4 s, voltage
gradient 5.5 V ⁄ cm; second, run time 20 h, initial switch time
14 s, ﬁnal switch time 30 s, voltage gradient 6 V ⁄ cm. Concate-
mers of bacteriophage kcI857Sam7 (Bio-Rad) and pBR328 (5-kb
ladder; Bio-Rad) were used as size markers.
PFGE patterns were interpreted according to the criteria of
Tenover et al. [14], and were also analysed with GelCompar
software (Applied Maths, Kortrijk, Belgium), using the Dice
coefﬁcient [15] and unweighted pair grouping by mathemat-
ical averaging (UPGMA), with 1% band tolerance and 0.5%
optimisation settings. Strain 11 ⁄ 01, exhibiting the predominant
PFGE type, was used as a reference standard and was
positioned in every sixth lane to allow normalisation of
electrophoretic patterns across the gel. A cut-off value of
95% similarity was used to deﬁne PFGE clones.
ClaI restriction fragment length polymorphism analysis of
vanA-related elements
The diversity of Tn1546-related transposons was analysed by
ampliﬁcation of an almost complete transposon sequence
with long PCR technology, followed by digestion of the
resulting amplicon with ClaI (New England BioLabs, Bever-
ly, MA, USA). DNA was isolated by guanidine-HCl extrac-
tion using a High Pure PCR Template Preparation Kit
(Roche Diagnostics, Mannheim, Germany). Ampliﬁcation
was performed in a TGradient thermocycler (Biometra,
Go¨ttingen, Germany) using DyNAzyme EXT DNA Polym-
erase (Finnzymes, Espoo, Finland), primers ORF1-F1 (AA-
TCTTCATTAAAGCTACCTGTCCG) and VanY-R1 (TAT-
CTCATAACGAAGATTAGTCGGC), and the PCR thermal
cycling conditions described previously [16].
RESULTS
Table 1 shows the annual frequency of isolation of
enterococci, including VRE. In total, 2647 Entero-
coccus spp. were isolated, of which 121 (4.6%)
were identiﬁed as VRE. The most frequent iso-
lates of VRE were VanA+ E. faecium (77.7%) and
VanB+ E. faecalis (9.9%). VanB+ E. faecium and
VanA+ E. faecalis together accounted for 12.4% of
VRE isolates.
Table 1. Occurrence of vancomycin-resistant enterococci
(VRE) at the Department of Haemato-Oncology, Olomouc
University Hospital, Czech Republic
1997 1998 1999 2000 2001 2002 Total
Absolute number of
enterococci isolated
630 495 397 412 344 369 2647
Absolute number of VRE 8 27 27 22 17 20 121
VRE (%) 1.3 5.5 6.8 5.3 4.9 5.4 4.6
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The results of vanA and vanB detection by
multiplex PCR agreed with the antimicrobial
susceptibility tests, i.e., high-level resistance to
both vancomycin (MIC >64 mg ⁄L) and teicopla-
nin (MIC >16 mg ⁄L) in VanA+ VRE, and resist-
ance to vancomycin (MIC >4 mg ⁄L) in VanB+
VRE. None of the isolates was resistant to linezo-
lid. Table 2 summarises the occurrence of VRE in
relation to the number of patients and the dur-
ation of their hospitalisation.
Table 3 summarises the occurrence of VRE in
clinical specimens from patients hospitalised in
the DHO during the follow-up period. VRE were
isolated most frequently from rectal swabs, urine,
sputum and blood. The frequency of isolation of
VRE from other clinical specimens was < 3%. The
DHO environment (instrument stands, bedsheets)
and samples from staff members (rectal and nasal
swabs, as well as swabs from hands, hair and
uniforms) yielded ﬁve VanA+ E. faecium isolates
(Table 4).
PFGE SmaI macrorestriction patterns of VanA+
E. faecium strains comprised 29–36 fragments of
size 13–410 kb (Fig. 1). Thirty-two different PFGE
patterns with 35–98% similarity were identiﬁed
[14], with three large macrorestriction groups (A,
B and C) separated at a similarity level of 65%;
macrorestriction patterns for isolates 2 ⁄ 00, 5 ⁄ 00
and 7 ⁄ 00 were unclustered. Two predominant
clonal types, designated A1 and C5, were identi-
ﬁed that contained 16 and 11 isolates, respect-
ively. The isolates within these clonal types
showed 95–100% similarity, and differed from
one another by 0–6 fragment positions. Clonal
type C5 was represented by strains predomin-
ating in 1998 and 1999, whereas clonal type A1
contained isolates from 2001 and 2002. The other
patterns were represented by either a single
isolate or by a pair of related isolates. The
dendrogram based on the PFGE analysis, together
with the corresponding antibiograms, is shown in
Fig. 2.
ClaI restriction fragment length polymorphism
analysis of Tn1546-like elements showed that 14
different Tn1546 subtypes, designated I–XIV,
could be distinguished among 59 VanA+ E. fae-
cium isolates (Fig. 2). For two isolates, 29 ⁄ 98 and
1 ⁄ 02, no ampliﬁcation product was generated
with the primers used. The predominant subtype
I was associated with 40 isolates, representing 14
clones, which suggests horizontal transmission of
VanA elements among non-related strains of
E. faecium. Tn1546 subtype I was not detected
among isolates belonging to macrorestriction
group B. The ClaI restriction endonuclease pattern
of the subtype I transposon differed from that of
the prototype Tn1546 (GenBank accession no.
M97297) [17] by an additional ClaI site. This
subtype was characterised by a pattern compris-
ing a 2.0-kb band, a double 2.9-kb band, and a 3.2-
kb band (not shown).
Among 22 clinically non-signiﬁcant isolates
obtained from rectal swabs, 16 unique PFGE
patterns were identiﬁed, while 32 isolates from
signiﬁcant clinical material yielded only ten
different PFGE patterns. Nine of the clinical
isolates belonged to clonal type C5, and 12
belonged to clonal type A1. Three of the VanA+
E. faecium isolates from environmental samples
(taken from an instrument stand, a nurse’s apron
and a nasal swab, respectively) had unique
PFGE patterns, but two environmental isolates,
Table 2. Occurrence of vancomycin-resistant enterococci
(VRE) in relation to the number of bed-days
Year
Absolute number
of bed-days
Absolute number
of VRE
VRE ⁄bed-days
· 1000
1997 10 844 8 0.74
1998 9694 27 2.79
1999 10 126 27 2.67
2000 9653 22 2.28
2001 10 003 17 1.70
2002 9738 20 2.05
Table 3. Occurrence of vancomycin-resistant enterococci
(VRE) in clinical samples from haemato-oncologic patients
Specimen Absolute number of VRE isolates Relative frequency (%)
Rectal swabs 67 55.4
Urine 24 19.8
Sputum 12 9.9
Blood 10 8.3
Other 8 6.6
Table 4. Occurrence of vancomycin-resistant enterococci
(VRE) in the Department of Haemato-Oncology environ-
ment and in specimens from members of staff
Specimen
Absolute
number
of specimens
Absolute number
of enterococci
isolated
Absolute
number
of VREa
Staff, stool 87 39 0
Staff, hands 91 8 0
Staff, other
(hair, uniform, nose)
314 28 3
Environment
(tables, wash-basins, etc.)
81 14 2
aAll VRE isolated were identiﬁed as VanA+ E. faecium.
Kolar et al. Genotyping of vancomycin-resistant E. faecium 355
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 353–360
520 ⁄ 99, isolated from a bedsheet, and 726 ⁄ 99,
isolated from the hair of a staff member, were
indistinguishable from patient isolates (urine
isolate 17 ⁄ 98 and intestinal isolate 43 ⁄ 99, respect-
ively).
One patient yielded two VanA+ E. faecium
isolates of clonal type C5 in 1998 (36 ⁄ 98) and
1999 (53 ⁄ 99), respectively. SmaI analysis of 53 ⁄ 99
revealed a shift in size for a single band of
c. 45 kb, indicating a deletion or mutation leading
to the generation of a new SmaI restriction site in
the existing 143-kb fragment. These two isolates
were presumed to be closely related and may be
derived from a common ancestor.
DISCUSSION
The selection and spread of VRE are worrying
trends in the development of bacterial resistance
and represent a substantial risk for hospitalised
patients. This is particularly important for hae-
mato-oncological patients, who are at increased
risk because of their impaired immunity. In VRE
with the VanA+ and VanB+ phenotypes, the
acquired resistance is transferable and is thus
particularly important from the epidemiological
and clinical viewpoints [18,19].
Clinical material from DHO patients has been
tested regularly for the presence of VRE since
1997 [9]. On average, 5% of all enterococci
isolated were VRE. Most often, VRE were iden-
tiﬁed as VanA+ E. faecium (78%) and VanB+
E. faecalis (10%). Since 55% of the isolates were
from rectal swabs, most VRE appeared to reﬂect
colonisation of the gastrointestinal tract in the
absence of infection. The increase in the preva-
lence of VRE, from 1.3% in 1997 to 5.4% in 2002,
may be associated with the selective pressure of
antibiotics and the transmission of strains via
environmental vectors, particularly the hands of
members of staff. Another potential source could
be the community, since some rectal swab isolates
from carriers were genotypically related to iso-
lates from sputum, urine and blood.
VRE are distributed worldwide, but their epi-
demiology appears to vary on a regional basis.
Thus, polyclonal isolates were described by
Padiglione et al. [20] in Australia, whereas some
European centres have reported nosocomial out-
breaks of VRE associated with very diverse
epidemiological situations [21–26].
PFGE has been proposed as the method of
choice for epidemiological typing of vancomycin-
resistant E. faecium [22,27–29], although alterna-
tive techniques, such as ampliﬁed fragment
length polymorphism and multilocus sequence
typing analysis, have also been used successfully
for the characterisation of isolates and the long-
term epidemiological analysis of enterococci
[30,31]. Although macrorestriction analysis does
not readily establish the degree of genetic relat-
edness of isolates with substantially different
PFGE patterns, it is a highly reproducible typing
method that is capable of distinguishing among
clonal populations of VRE. Moreover, grouping of
isolates by PFGE correlates well with the results
obtained by other typing techniques [24,25,32]. In
the present study, PFGE identiﬁed 32 unique
restriction patterns with a similarity ranging from
65% to 98%, which is comparable to the high
Fig. 1. Representative SmaI macrorestriction
fragment patterns from VanA+ Enterococcus
faecium isolates.
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intra-species genomic variability seen in E. fae-
cium isolates from various sources [33]. The
spread of two predominant clonal types contain-
ing identical or closely related isolates was iden-
tiﬁed.
The recognition of 16 different clonal types in
the genetically heterogeneous sub-population of
clinically non-signiﬁcant isolates, but only ten
clonal types among the clinically signiﬁcant iso-
lates, may reﬂect the fact that most isolates from
Fig. 2. Dendrogram showing the similarity levels of the SmaI macrorestriction patterns of 59 VanA+ Enterococcus faecium
isolates. The isolates are designated by capital letters indicating their isolation source (R, rectal swabs; U, urine; S, sputum;
B, blood; H, hospital environment), together with a number ⁄ year of isolation. Two predominant clonal types with cut-off
values of 95% similarity are indicated by vertical lines. SmaI pulsed-ﬁeld gel electrophoresis (PFGE) types and subtypes of
Tn1546-like elements obtained by ClaI long PCR restriction fragment length polymorphism analysis are indicated by
Roman numerals (NT, non-typeable). Antibiograms (V, resistance to vancomycin; E, resistance to erythromycin; A,
resistance to ampicillin; F, resistance to nitrofurantoin; T, resistance to tetracycline; C, resistance to chloramphenicol; S,
high-level resistance to streptomycin; and G, high-level resistance to gentamicin) are indicated on the right.
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rectal swabs represent carrier isolates that may be
community-acquired. Nevertheless, the fact that
some isolates from the gastrointestinal tract had
PFGE patterns indistinguishable from those of
epidemic strains isolated from clinical material
suggests that hospital-related transmission of
VRE and colonisation with VRE following admis-
sion cannot be excluded. Faecal carriage of the
outbreak strains was found almost exclusively
among patients on the haematology or haemato-
oncology wards, as has been reported in other
studies [34–36]. In contrast, the genotypic simi-
larity of isolates from clinical material such as
blood, urine and sputum indicates successful
intra-hospital transmission of a speciﬁc hospital-
adapted genetic lineage, which may result in the
endemicity of VRE. Recent evolutionary genetics
and population structure studies have identiﬁed a
genetic lineage of E. faecium that has acquired
vancomycin resistance through horizontal trans-
fer and has spread globally [37]. The epidemiol-
ogy of VRE at the DHO appears to be complex
and is inﬂuenced by both the clonal spread of
epidemic strains and the horizontal transfer of
Tn1546-like elements among strains in the envi-
ronment. Similar ﬁndings have been reported
from other European hospitals [38].
Two vancomycin-resistant isolates of VanA+
E. faecium, isolated from a bedsheet and the hair
of a nurse (who was in direct contact with
hospitalised patients), were identical with isolates
from patients. This indicates the possibility of
colonisation of members of staff and subsequent
transfer to hospitalised patients, particularly via
the hands of staff. A previous study has also
suggested that wastewater in a commode enabled
the spread of VRE in aerosols or by contact with
hands or clothes [39].
The ﬁnding of unique genotype proﬁles for
some of the isolates analysed indicates that they
may be of endogenous origin, and perhaps have
been selected by broad-spectrum antibiotics. This
may mean that a patient carries VRE as a part of
their gastrointestinal microﬂora at the time of
hospital admission. Treatment of bacterial infec-
tions or prophylactic administration of broad-
spectrum antibiotics results in the selection and
multiplication of VRE. The evidence that a VanA+
E. faecium strain persisted in the gastrointestinal
tract of one patient for 2 years supports this
hypothesis. A high prevalence of enterococci
among high-risk patients in haemato-oncology
wards has also been reported in other countries
[40,41]. Prolonged hospital stay, previous hospi-
talisation and admission to an intensive care unit,
male gender and antibiotic usage are considered
to be risk-factors associated with acquisition of
VRE by haemato-oncology patients [42,43].
VRE, including VanA+ E. faecium isolates, have
been identiﬁed previously in this community in
the Czech Republic [44]. The presence of these
strains in the European Community might be
caused by transmission from domestic and farm
animals colonised as a consequence of using
animal feeds containing glycopeptides [45]. This
is an agricultural regionwith an intensive livestock
industry that used avoparcin until the enforce-
ment of the European ban in 1997. VanA+ E. fae-
cium strains have been identiﬁed in the area in
hospitalised patients, in healthy individuals, and
also in poultry [44,46]. Thus, the ban on the use of
avopacinmay play an important role in preventing
the spread of VRE in the human population.
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